Baseline Circulating Cell‐free Dna Load Is Related To, but Adds Prognostic Value to Metabolic Tumor Burden Measured by FDG Pet/Ct in Follicular Lymphoma

Abstract

Conclusion:The updated clinical results of the FIL-MCL0208 trial show that: i) both TP53 and KMT2D mutations independently associate with shorter PFS and OS in younger MCL patients receiving high-dose therapy; ii) KMT2D mutations seem to be as detrimental as TP53 mutations, at least in terms of PFS; iii) given the negative prognostic impact of these mutations, they might be used to select high-risk patients for novel therapeutic approaches.